- Trials with a EudraCT protocol (7)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
7 result(s) found for: Lead oxide.
Displaying page 1 of 1.
EudraCT Number: 2011-000203-41 | Sponsor Protocol Number: AC-052-391 | Start Date*: 2011-09-06 | |||||||||||
Sponsor Name:Actelion Pharmaceuticals Ltd. | |||||||||||||
Full Title: Multicenter, double-blind, placebo-controlled, randomized, prospective study of bosentan as adjunctive therapy to inhaled nitric oxide in the management of persistent pulmonary hypertension of the ... | |||||||||||||
Medical condition: Persistent Pulmonary Hypertension of the Newborn (PPHN) | |||||||||||||
|
|||||||||||||
Population Age: Preterm newborn infants, Newborns, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) NL (Not Authorised) CZ (Prematurely Ended) GB (Completed) FR (Ongoing) BE (Prematurely Ended) PL (Prematurely Ended) Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-011638-90 | Sponsor Protocol Number: 08082GM-A | Start Date*: 2009-11-09 |
Sponsor Name:Belfast Health and Social Care Trust | ||
Full Title: Targeting microvascular dysfunction in young hypertensive patients. | ||
Medical condition: Hypertension | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2012-001829-27 | Sponsor Protocol Number: AC-052-392 | Start Date*: Information not available in EudraCT | |||||||||||
Sponsor Name:Actelion Pharmaceuticals Ltd. | |||||||||||||
Full Title: Multi-center non-drug-interventional extension study to assess long-term safety and effects on growth in patients who received bosentan or placebo as adjunctive therapy to inhaled nitric oxide for ... | |||||||||||||
Medical condition: Persistent Pulmonary Hypertension of the Newborn (PPHN) | |||||||||||||
|
|||||||||||||
Population Age: Preterm newborn infants, Newborns, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) CZ (Completed) PL (Completed) FR (Ongoing) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-001517-32 | Sponsor Protocol Number: K-877-201 | Start Date*: 2013-10-02 | |||||||||||
Sponsor Name:Kowa Research Europe | |||||||||||||
Full Title: A dose finding study to assess the safety and efficacy of K-877 in patients with statin-controlled LDL-C but abnormal lipid levels | |||||||||||||
Medical condition: dyslipidemia (eg hyperlipidaemia, hypertriglyceridaemia) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Completed) GB (Completed) HU (Completed) DE (Completed) CZ (Completed) NL (Completed) DK (Completed) PL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-014551-80 | Sponsor Protocol Number: 1268.16 | Start Date*: 2010-01-21 | |||||||||||
Sponsor Name:BOEHRINGER ING. | |||||||||||||
Full Title: Randomised, double-blind, double-dummy, placebo-controlled, parallel group study to assess the efficacy and safety of 6 weeks of oral BI 671800 ED 400 mg b.i.d., Montelukast 10 mg q.d., or placeb... | |||||||||||||
Medical condition: patients with symptomatic asthma on inhaled corticosteroids | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) SE (Completed) DE (Completed) GB (Completed) AT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-003544-20 | Sponsor Protocol Number: 207972 | Start Date*: 2018-02-08 | |||||||||||
Sponsor Name:GlaxoSmithKline Research & Development Ltd | |||||||||||||
Full Title: A double blind (sponsor open) placebo-controlled, stratified, parallel group study to evaluate the efficacy and safety of repeat doses of GSK3772847 in participants with moderate to severe asthma w... | |||||||||||||
Medical condition: asthma with allergic fungal airway disease (AFAD). | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) FR (Completed) NL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-001927-15 | Sponsor Protocol Number: TV48574-AS-20031 | Start Date*: 2021-02-22 | |||||||||||
Sponsor Name:Teva Branded Pharmaceutical Products R&D, Inc. | |||||||||||||
Full Title: A 16-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Proof-of-Concept Study to Evaluate the Efficacy and Safety of TEV-48574 in Adults with T2-low/non-T2 Severe Uncontrolled Asthma | |||||||||||||
Medical condition: T2-low/non-T2 Severe Uncontrolled Asthma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) BG (Prematurely Ended) CZ (Prematurely Ended) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
